HIV Protease

• 

  Subject Areas on Research

  • A simple Escherichia coli system for monitoring HIV protease activity: analysis of two temperature-sensitive protease mutants. 
  • Analysis of partial pol and env sequences indicates a high prevalence of HIV type 1 recombinant strains circulating in Gabon. 
  • Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. 
  • Dendritic cells/natural killer cross-talk: a novel target for human immunodeficiency virus type-1 protease inhibitors. 
  • Design, synthesis and evaluation of a potent substrate analog inhibitor identified by scanning Ala/Phe mutagenesis, mimicking substrate co-evolution, against multidrug-resistant HIV-1 protease. 
  • Developing an HIV vaccine. 
  • Development of a novel screen for protease inhibitors. 
  • Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. 
  • Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response. 
  • Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene. 
  • HIV evolutionary genetics. 
  • Human immunodeficiency virus type 1 protease genotype predicts immune and viral responses to combination therapy with protease inhibitors (PIs) in PI-naive patients. 
  • Identification of cis-acting repressor activity within human immunodeficiency virus type 1 protease sequences. 
  • Impact of genotypic resistance testing on physician selection of antiretroviral therapy. 
  • Intrinsic activity of human immunodeficiency virus type 1 protease heterologous fusion proteins in mammalian cells. 
  • Lack of protease inhibitor resistance following treatment failure--too good to be true? 
  • Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection. 
  • Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. 
  • Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease. 
  • Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection. 
  • Overcoming resistance: virologic response to a salvage regimen with the combination of ritonavir plus indinavir. 
  • Parallel evolution of drug resistance in HIV: failure of nonsynonymous/synonymous substitution rate ratio to detect selection. 
  • Phylogenetic analysis of protease and transmembrane region of HIV type 1 group O. 
  • Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen. 
  • Potent inhibition of human immunodeficiency virus type 1 (HIV-1) replication by inducible expression of HIV-1 PR multimers. 
  • Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. 
  • Sculpting proteins interactively: continual energy minimization embedded in a graphical modeling system. 
  • Simultaneous detection of major drug resistance mutations in the protease and reverse transcriptase genes for HIV-1 subtype C by use of a multiplex allele-specific assay. 
  • Substrate analogue inhibition and active site titration of purified recombinant HIV-1 protease. 
  • Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores. 
  • Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant.